Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240334 | 0.85 | NCF1 (0.68) | NCF1KDM4EALDH1A1HRH3KMT2A | |
| SCHEMBL21730436 | 0.84 | NCF1 (0.66) | NCF1KDM4EALDH1A1HRH3KMT2A | |
| Trifluoroacetic Acid SCHEMBL2267986 | 0.79 | SIGMAR1 (0.57) | KDM4EALDH1A1HRH3KMT2A | |
| Trifluoroacetic Acid SCHEMBL2267982 | 0.79 | SIGMAR1 (0.57) | KDM4EALDH1A1HRH3KMT2A | |
| Trifluoroacetic Acid SCHEMBL2269036 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1HRH3KMT2A | |
| Trifluoroacetic Acid SCHEMBL23853580 | 0.77 | HRH3 (0.57) | HRH3KMT2AKCNJ1 | |
| SCHEMBL1444172 | 0.77 | NCF1 (0.56) | NCF1KDM4EALDH1A1HDAC1HDAC8 | |
| SCHEMBL23696005 | 0.75 | ALDH1A1 (0.62) | NCF1KDM4EALDH1A1HRH3KMT2A | |
| SCHEMBL27401886 | 0.74 | HTR1A (0.52) | NCF1KDM4EALDH1A1HDAC6HRH3 | |
| SCHEMBL1443492 | 0.73 | NCF1 (0.51) | NCF1KDM4EALDH1A1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | NCF1 1517/4885KDM4E 2806/4885ALDH1A1 3283/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | NCF1 1606/4885KDM4E 2968/4885ALDH1A1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.